RESSTORE: a Multicentric and European clinical trial 2015-2020

RESSTORE, REgenerative Stem cell therapy for STroke in Europe, is a multicentric project in Personalising health and care (PHC) area financed by the European Commission H2020 programme. The RESSTORE project is focused on the assessment of the efficacy of intravenous cell therapy to improve recovery and/or compensation after ischemic stroke. The RESSTORE consortium consists of 28 partners, including 23 clinical centers, 5 cell therapy units, 5 experimental laboratories, 1 Clinical Research Organisation. The project, co-coordinated by Dr Olivier Detante (CHU Grenoble, France) and Pr Exuperio DIEZ TEJEDOR (SERMAS, Madrid, Spain), will recruit 400 patients from the Czech Republic, Finland, France, Spain, Scotland and deliver new knowledge on the fast growing area of regenerative medicine. The project started in September 2015 and will receive funding from the European Commission for 5 years.

Disclaimer: The RESSTORE project and associated cell therapy is an experimental study with a well defined scientific scope which adheres to the most stringent regulatory and ethical requirements. Patient recruitment follows a strict procedure (inclusion/exclusion criteria according to a large range of variables), applied by clinical experts in all partnering centres to meet the boundaries defined in the study protocol. 

The RESSTORE cellular therapy is (as one of the major inclusion criterias amongst several others) specifically targeted to individuals who suffered from a particular type of stroke (hemispheric, ischemic stroke) and who can be enroled in the study after 1-4 days post-stroke

NCT number: NCT02849613 and EudraCT number: 2016-001902-40

Latest news

Najlepsze tabletki na powiększenie penisa – zobacz tutaj

Tabletki na powiększenie członka

Najlepsze tabletki na powiększenie biustu – sprawdź

Tabletki na powiększenie piersi

The first RESSTORE Newsletter is out!

RESSTORE is a challenging European project to develop reparative medicine for stroke patients. Improving patients’ recovery requires experts of cell therapy products, neurosciences, and stroke neurology. Innovative multimodal MRI and statistics also increase our knowledge about stroke pathophysiology and treatment effects.
While we have just obtained the regulatory and ethics approval, we will start the clinical trial in the next weeks. It is our pleasure to present here the first RESSTORE newsletter on behalf of the European consortium including France, Spain, Finland, Czech Republic and UK.19 Jun 2018 – 09:40

Frequent sauna bathing reduces risk of stroke

Frequent sauna bathing is associated with a reduced risk of stroke, according to a new international study. In a 15-year follow-up study, people taking a sauna 4-7 times a week were 61% less likely to suffer a stroke than those taking a sauna once a week. This is the first prospective large-scale study on this topic, and the findings were reported in Neurology.

Stroke is one of the leading causes of disability worldwide, placing a heavy human and economic burden on societies. The reduced risk associated with sauna bathing was found by a team of scientists from the Universities of Eastern Finland, Bristol, Leicester, Atlanta, Cambridge and Innsbruck.4 May 2018 – 15:38

RESSTORE 2nd Annual Meeting, Seville, 6th & 7th November 2017

RESSTORE 2nd Annual Meeting took place in Seville on 6th and 7th November 2017. Workpackages progress was presented to the whole consortium and workshops on cell production, clinical trial and experimental work were organised. 


XXVI Annual Congress of the ESGCT 2018, Lausanne (Switzerland)

Tuesday, October 16, 2018 to Friday, October 19, 2018

The European Society of Gene and Cell Therapy (ESGCT) organises an Annual Congress, which brings together scientists working in the fields of gene and cell therapy from throughout Europe and beyond.

7th Annual Cell Culture & Bioprocessing Congress, London (UK)

Thursday, October 25, 2018 to Friday, October 26, 2018

The congress will gather over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions. There will be 40 presentations, case studies and panel discussions focused on the key issues in cell line optimisation, process development and biological production.All agenda items


Copyright © 2016